Alistair James Henry

Title: Alistair James Henry: Innovator in Anti-IgE Antibodies

Introduction

Alistair James Henry is a notable inventor based in Slough, GB. He has made significant contributions to the field of biotechnology, particularly in the development of anti-IgE antibodies. With a total of 8 patents to his name, his work has the potential to impact the treatment of various allergic and autoimmune disorders.

Latest Patents

Henry's latest patents focus on improved anti-IgE antibodies and antigen binding agents. These inventions target IgE, which is crucial for treating disorders caused by IgE, such as allergic responses and certain autoimmune conditions. One of his key innovations relates to novel mutants of omalizumab (Xolair®), which may exhibit enhanced affinity for IgE and improved interactions with the Cε2 domain of IgE. Additionally, he has developed thiophene derivatives that are useful for treating disorders caused by IgE, including allergies and type 1 hypersensitivity.

Career Highlights

Throughout his career, Alistair James Henry has worked with prominent companies in the biotechnology sector, including Amgen Inc. and UCB Biopharma. His experience in these organizations has allowed him to refine his expertise in the development of therapeutic agents targeting IgE.

Collaborations

Henry has collaborated with notable professionals in his field, including Martyn Kim Robinson and John A. Latham. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Alistair James Henry's innovative work in the field of anti-IgE antibodies showcases his commitment to improving treatments for allergic and autoimmune disorders. His contributions are significant and continue to influence the biotechnology landscape.